ART812（Cat No.:I044429）is a potent, selective small-molecule inhibitor of the KRAS G12C mutant, an oncogenic variant commonly found in non-small cell lung cancer (NSCLC) and other solid tumors. It covalently binds to the cysteine residue in the switch II pocket of KRAS G12C, locking the protein in its inactive GDP-bound state and preventing downstream MAPK signaling. ART812 demonstrates strong antitumor activity in preclinical models by selectively targeting mutant KRAS while sparing wild-type KRAS. It is a valuable tool in precision oncology research focused on targeting RAS-driven cancers.